Roche inks $80M upfront deal for Hansoh’s cancer ADC

Roche is spending $80 million upfront for global rights to Hansoh Pharma’s colorectal cancer candidate, which is an early-stage ADC that targets the CDH17 protein. Hansoh could get up to $1.45 billion in milestones, as ...